SK’s Narcolepsy Therapy Ready For U.S. Phase III Trial
This article was originally published in PharmAsia News
South Korean conglomerate SK Group is making some progress in new drug development, with its affiliate SK Biopharmaceuticals poised to begin Phase III clinical trials in the U.S. with a treatment for narcolepsy.
You may also be interested in...
Vaccine specialist SK Bioscience is set to launch potentially South Korea’s biggest biopharma IPO next month on the back of a growing premium vaccine business, new opportunities in COVID-19 vaccines and its contract manufacturing operations.
Amid the highly successful launch of COVID-19 vaccines using the technology by Pfizer/BioNTech and Moderna, South Korean bioventure OliX Pharmaceuticals is diversifying into the mRNA field by establishing a new subsidiary that focuses on R&D into new vaccines and therapeutics using the platform.
Plus deals involving Scynexis/Hansoh, Cend/Qilu, Apollomics/Edison, Apollomics/Iterion, Apollomics/Nuance, Aerami/Chance, Antibe/Nuance, Ildong/Arbormed